Active — Not RecruitingPhase 3

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

United States371 participantsStarted 2024-09-11

Plain-language summary

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Lymphoproliferative disorder
✕. active malignancy
✕. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
✕. thrombosis or cerebrovascular ischemic event disease within the last 12 months
✕. a high risk for herpes zoster reactivation
✕. active or recent infections

What they're measuring

Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48

Timeframe: 48 weeks

Trial details

NCT IDNCT06431373

SponsorPriovant Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09-11

View on ClinicalTrials.gov More Uveitis, Posterior trials